The consolidated gross margin stood at 71 per cent with reported EBITDA margin at 30 per cent

Thyrocare Technologies has announced the results for the quarter ended June 30, 2025.

In Q1FY26, the consolidated revenue saw a YoY increase of 23 per cent, driven by a 25 per cent growth in pathology and a 6 per cent growth in radiology. In the pathology business, the franchise revenue grew by 20 per cent YoY, while partnership revenue surged by 36 per cent YoY. The total test volume reached 46.9 million in Q1FY26, reflecting a 15 per cent YoY increase. The consolidated gross margin stood at 71 per cent with reported EBITDA margin at 30 per cent. Consolidated reported EBITDA grew by 37 per cent YoY, while PAT saw a significant YoY increase of 62 per cent. The company opened new labs in Bhagalpur, Kashmir and Roorkee.